Demirel Hüseyin Cihan, Davis John Warren
University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Turk J Urol. 2018 Mar;44(2):93-102. doi: 10.5152/tud.2018.56056. Epub 2018 Mar 1.
Multiparametric magnetic resonance imaging (mpMRI) has managed to change the paradigms on prostate cancer detection and risk classification. The most clear-cut indication of mpMRI in guidelines is the patients with a history of negative biopsy/increasing prostate-specific antigen (PSA), and presence of additional findings supporting its use in non biopsied patients and active surveillance. mpMRI complements standard clinical exam, PSA measurements, and systematic biopsy, and will miss some tumors that lack enough size or change in tissue density. Use of mpMRI is likely to increase, and further developments in the technique will be important for safe adoption of focal therapy concepts. Here we present a brief summary about mpMRI and its use in detection, risk classification and follow-up of prostate cancer.
多参数磁共振成像(mpMRI)已成功改变了前列腺癌检测和风险分类的模式。指南中mpMRI最明确的指征是有活检阴性/前列腺特异性抗原(PSA)升高病史的患者,以及存在支持其用于未活检患者和主动监测的其他发现。mpMRI补充了标准临床检查、PSA测量和系统活检,但会遗漏一些体积不足或组织密度未改变的肿瘤。mpMRI的使用可能会增加,该技术的进一步发展对于安全采用局部治疗概念至关重要。在此,我们简要总结一下mpMRI及其在前列腺癌检测、风险分类和随访中的应用。